The patent badge is an abbreviated version of the USPTO patent document. The patent badge does contain a link to the full patent document.
The patent badge is an abbreviated version of the USPTO patent document. The patent badge covers the following: Patent number, Date patent was issued, Date patent was filed, Title of the patent, Applicant, Inventor, Assignee, Attorney firm, Primary examiner, Assistant examiner, CPCs, and Abstract. The patent badge does contain a link to the full patent document (in Adobe Acrobat format, aka pdf). To download or print any patent click here.
Patent No.:
Date of Patent:
Jun. 12, 2018
Filed:
Feb. 11, 2016
Applicant:
Ablynx N.v., Zwijnaarde, BE;
Inventors:
Jason E. Fernandez, Brookline, MA (US);
Daniel A. Dixon, Arlington, MA (US);
Andrea Paulson, Somerville, MA (US);
Assignee:
Ablynx N.V., Ghent-Zwijnaarde, BE;
Attorney:
Primary Examiner:
Int. Cl.
CPC ...
C07K 16/00 (2006.01); C07K 1/00 (2006.01); C12P 21/08 (2006.01); A61K 39/395 (2006.01); A61K 9/00 (2006.01); A61K 9/19 (2006.01); A61K 47/10 (2017.01); A61K 47/26 (2006.01); G06Q 99/00 (2006.01); A61K 9/16 (2006.01); C07K 16/18 (2006.01); C07K 16/24 (2006.01); G01N 33/15 (2006.01); A61K 39/00 (2006.01);
U.S. Cl.
CPC ...
A61K 39/39591 (2013.01); A61K 9/0019 (2013.01); A61K 9/1617 (2013.01); A61K 9/1623 (2013.01); A61K 9/1641 (2013.01); A61K 9/19 (2013.01); A61K 47/10 (2013.01); A61K 47/26 (2013.01); C07K 16/18 (2013.01); C07K 16/241 (2013.01); G01N 33/15 (2013.01); G06Q 99/00 (2013.01); A61K 2039/507 (2013.01); C07K 2317/22 (2013.01); C07K 2317/24 (2013.01); C07K 2317/565 (2013.01); C07K 2317/569 (2013.01);
Abstract
The invention relates to formulations of single domain antigen binding molecules, e.g., nanobody molecules, in particular formulations of TNF-binding nanobody molecules. The single domain antigen binding molecules can include one or more single binding domains that interact with, e.g., bind to, one or more target proteins. The formulations are useful, e.g., as pharmaceutical formulations. Method of preparing, and using the formulations described herein, to treat, e.g., TNF-associated disorders, are also disclosed.